Posted by Michael Wonder on 09 Nov 2021
Merck and Ridgeback announce U.S. Government to purchase 1.4 million additional courses of molnupiravir, an investigational oral anti-viral medicine, for the treatment of mild to moderate COVID-19 in at risk adults
9 November 2021 - Merck and Ridgeback Biotherapeutics today announced that the United States Government will exercise two of its options to purchase a total of 1.4 million additional courses of molnupiravir, an investigational oral anti-viral medicine, if the medicine is granted emergency use authorisation or approval by the U.S. FDA, for approximately $1 billion.
With these exercised options, the U.S. Government has now committed to purchase a total of approximately 3.1 million courses of molnupiravir, for approximately $2.2 billion, between authorization and early 2022.
